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Abstract
Up-regulation of the membrane-bound efflux pump P-glycoprotein (P-gp) is associated with the phenomenon of
multidrug-resistance in pathogenic organisms, including protozoan parasites. In addition, P-gp plays a role in normal
physiological processes, however our understanding of these P-gp functions remains limited. In this study we investigated
the effects of the P-gp inhibitor GF120918 in Toxoplasma gondii, a model apicomplexan parasite and an important human
pathogen. We found that GF120918 treatment severely inhibited parasite invasion and replication. Further analyses of the
molecular mechanisms involved revealed that the P-gp inhibitor modulated parasite motility, microneme secretion and
egress from the host cell, all cellular processes known to depend on Ca
2+ signaling in the parasite. In support of a
potential role of P-gp in Ca
2+-mediated processes, immunoelectron and fluorescence microscopy showed that T. gondii P-
gp was localized in acidocalcisomes, the major Ca
2+ storage in the parasite, at the plasma membrane, and in the
intravacuolar tubular network. In addition, metabolic labeling of extracellular parasites revealed that inhibition or down-
regulation of T. gondii P-gp resulted in aberrant lipid synthesis. These results suggest a crucial role of T. gondii P-gp in
essential processes of the parasite biology and further validate the potential of P-gp activity as a target for drug
development.
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Introduction
The integral membrane protein P-glycoprotein (P-gp, MDR1,
ABCB1) is one of the most studied cellular transporters of the
ATP-binding cassette (ABC) transporter superfamily [1]. The
clinical importance of P-gp derives from the fact that over-
expression of this transporter is commonly associated with the
phenomenon of multidrug resistance [2], a major public health
problem derived from drug-resistant cancer cells and microbial
pathogens. The main function of P-gp is the export of xenobiotics
from the cell, as corroborated by the findings that P-gp deficient
mice are viable but show strikingly altered pharmacokinetics and
increased sensitivity to a variety of drugs [3]. In addition to this
well known role, an increasing amount of evidence now suggests
that P-gp also participates in normal physiological processes,
including the transport of steroid hormones [4] and lipid
translocation (rev. in [5]).
Here we investigated the effects of the potent P-gp inhibitor
GF120918 in the biology of Toxoplasma gondii,am o d e l
intracellular parasite and an important human pathogen,
causing toxoplasmosis. Previous studies based on efflux analyses
in the presence of P-gp inhibitors suggested that an active P-gp
homologue is present in T. gondii [6,7]. Recently, two P-gp
homologues with the typical P-gp structure have been identified
i nt h eg e n o m eo ft h ep a r a s i t e( T g A B C . B 1a n dT g A B C . B 2 )a n d
found to be constitutively expressed in both the vegetative and
quiescent stages of T. gondii’s life cycle [8]. Further molecular
characterization revealed that TgABC.B1 is coded by a single
copy gene, expressed as a membrane-associated protein of ,150
kDa, and constitutively present in different parasite strains [9].
Indications that T. gondii P-gp may be involved in key biological
processes, such as replication and host cell invasion were
provided by early works using P-gp inhibitors [6,10]. However,
given that these studies used host cells containing P-gp, it was
not possible to discriminate between the contribution of T. gondii
and host cell P-gp. Indeed, we recently showed that host cell P-
gp plays a crucial role in T. gondii replication by facilitating the
transport of host cholesterol to the parasite vacuole [11]. In this
study we used P-gp deficient host cells [3] in parallel with
pharmacological inhibition ofP - g p ,t h e r e b ye n a b l i n gm o r e
selective insights into the specific role of T. gondii P-gp.
Inhibition of parasite P-gp was achieved with the acridonecar-
boxamide derivative GF120918, a potent competitive P-gp
inhibitor of the latest generation [12,13], whose use has been
widely published both in vitro [14] and in vivo [15,16].
Importantly, GF120918 does not inhibit the P-gp-related
multidrug transporters MRP1 and MRP2 [17] nor cytochrome
P450 3A, a key enzyme in drug metabolism [18], and achieves
adequate P-gp inhibition in vivo without significant side effects
[13,19].
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GF120918 inhibits parasite invasion
As an obligate intracellular parasite, T. gondii depends
completely on host cells for its survival and propagation; thus
host cell invasion is an essential process in the parasite’s biology.
To analyze whether P-gp inhibition compromises parasite
invasion, we blocked P-gp function in isolated parasites with
GF120918, a potent P-gp inhibitor of the latest generation [13].
GF120918 was found to strongly hamper P-gp function in the
parasite at low micromolar concentrations, as assessed by efflux
analysis of the specific P-gp substrate rhodamine 123 (Fig. 1A). To
analyze whether GF120918 inhibits parasite invasion, parasites
were pre-treated with the inhibitor for 30 min at 37uC and allowed
to infect host cells wild type (WT) or deficient in the two mouse P-
gp isoforms (P-gp DKO) [3] for 4 h in presence of the drug.
GF120918 was then removed and the infection was determined by
counting the parasite vacuoles after 24 h incubation. GF120918
treatment reduced the number of intracellular vacuoles by 50% in
both host cell types, indicating that host P-gp is not involved in
parasite invasion (Fig. 1B, white bars). Importantly, the invasion
inhibition was not caused by parasite lethality following compound
treatment, as GF120918 did not significantly compromise parasite
viability at the concentration inhibitory for invasion (Fig. 1F). To
analyse whether the presence of GF120918 at the time of infection
was necessary for the inhibitory effect, parasites were pre-treated
with GF120918, washed and incubated with host cells in absence
of the drug. Also in these experimental conditions, parasite
invasion was reduced by ,50% (Fig. 1B, grey bars), confirming
that the drug inhibited parasite invasion by acting solely on the
parasite. These results also showed that the invasion inhibition is
not reversed by removal of the drug from the medium, suggesting
that GF120918 stably inhibited the parasite target.
Having shown that GF120918 inhibited parasite invasion, we
then further dissected the inhibitory effect using a sequential
staining method, which allows discrimination between the
processes of adhesion to a host cell and active invasion. P-gp
DKO host cells were used during GF120918 treatment to exclude
the contribution of any residual host P-gp activity to the observed
phenotype. Parasites were pre-treated for 30 min at 37uC with
GF120918 and allowed to infect host cells for 2 h in presence of
the drug. In these experimental conditions parasite adhesion and
invasion were reduced by ,50% compared with control cells
(Fig. 1C, pre-treatment). This dual inhibition is indicative of an
effect on parasite attachment, since attachment is required for
invasion [20]. Interestingly, in the absence of parasite pre-
treatment, the inhibitory effect of GF120918 on parasite adhesion
and invasion was less pronounced (Fig. 1C, no pre-treatment),
suggesting that a time delay after adding the compound is
necessary for the inhibitory effect to occur.
To further analyze the time dependency of GF120918 effect on
parasite invasion, we pre-treated the parasites with the inhibitor
for 30 min at 37uCo r4 uC, to minimize the secretion of proteins
required for invasion, and we compared adhesion and invasion
after 15 min of host cell contact in the presence of the drug.
Fig. 1D shows that at these short invasion times GF120918,
treatment promoted both parasite adhesion and invasion com-
pared with control cells. This time dependent GF120918 effect on
parasite invasion was reminiscent of the phenotype observed upon
treatment with the Ca
2+ ionophore A23187. A23187 is a potent
modulator of Ca
2+-dependent processes in the parasite, including
secretion of microneme proteins required for motility and
invasion. However, prolonged stimulation of microneme secretion
inhibits parasite invasion ([21,22]), presumably due to the
exhaustion of factors required for the invasion process. In
agreement with these previous findings and similar to our
observations in GF120918 treated cells, short incubation times
with A23187 promoted parasite invasion, while prolonged A23187
exposure was detrimental (Fig. 1E).
GF120918 treatment increases T. gondii motility
From the above experiments we established that GF120918
modulates parasite invasion. As GF120918 increased parasite
invasion at short incubation times and the invasion process
depends on parasite motility (reviewed in [23]), we next examined
whether GF120918 treatment increased T. gondii motility as well.
Parasite motility was analyzed by allowing parasites to glide on a
substratum in presence or absence of GF120918 and visualizing
the trails produced by parasite movement by immunofluorescence
[24]. Parasites pre-treated with GF120918 for 30 min at 4uC
produced more (Fig. 2A, white bars) and longer trails (Fig. 2B)
compared with control cells. Parasite motility is known to be
regulated by intracellular Ca
2+ fluxes [21,25]. To test whether the
alteration of parasite motility induced by GF120918 treatment
correlated with the effects of Ca
2+ deregulation, we increased
intracellular calcium levels using the Ca
2+ ionophore A23187. In
our experimental conditions, both P-gp inhibitor and A23187
incubations increased parasite motility in a comparable manner
(Fig. 2A, gray bars). In addition, when parasites were co-treated
with GF120918 together with the Ca
2+ chelator BAPTA, the
increase in motility was reduced compared with parasites solely
treated with GF120918 (Fig. 2C). Collectively, these findings
indicated that GF120918 treatment increases parasite motility and
that this increase is likely to depend on alterations in parasite’s
Ca
2+ fluxes.
GF120918 treatment induces microneme secretion
Secretion of micronemes, secretory organelles located at the
apical end of the parasite, depends on Ca
2+ fluxes in the parasite
and it is essential for T. gondii motility [21]. To analyse whether
GF120918 affected microneme secretion, we examined the
discharge of the microneme protein MIC2, which is secreted on
the parasite surface and then shed after proteolytic processing
[26]. Parasites treated for 5 and 30 min with GF120918 showed a
time dependent increase in MIC2 surface staining compared with
control cells (Fig. 3A). Population-wide quantification by flow
cytometry revealed that MIC2 surface staining in non-permeabi-
lized cells increased following GF120918 treatment in ,25% of
the cells (Fig. 3B, thick lines). The staining was not due to cell
permeabilization induced by inhibitor treatment, as detergent-
permeabilized cells showed a much stronger signal (Fig. 3B, thin
lines). In addition, analysis of permeabilized cells revealed that in
control samples 64.44% of the total cell number (n=10’000)
showed high MIC2 signal, while GF120918 treatment decreased
this number to 48.47%, suggesting a loss of cell associated MIC2
following secretion, further confirmed by Western blot analysis of
MIC2 recovered in the culture supernatant (Fig. S2). Collectively,
these data indicate that GF120918 treatment induced microneme
secretion without increasing the permeability of parasite plasma
membrane.
GF120918 treatment induces parasite egress
As we observed that GF120918 treatment of extracellular T.
gondii enhanced parasite motility, we reasoned that if GF120918
could activate motility also in intracellular parasites, it would
promote active egress of T. gondii from the host cells, a process
which depends on parasite motility and is triggered by changes in
the host cells ionic environment [27]. When infected cultures were
GF120918 and Toxoplasma Gondii
PLoS ONE | www.plosone.org 2 April 2010 | Volume 5 | Issue 4 | e10062Figure 1. GF120918 treatment inhibits parasite invasion. A. Functionality assay of P-gp in isolated T. gondii treated with the indicated
inhibitor concentrations as measured by time course analysis of intracellular rhodamine 123 (Rho 123) retention. Retention is expressed as
percentage of mean fluorescence of intracellular Rho 123 at time 0. B. Invasion assay in presence of 10 mM GF120918 (GF) or solvent (cntl). T. gondii
were pre-treated with GF120918 for 30 min and allowed to infect wild type (WT) or P-gp deficient (DKO) host cell monolayers in presence of
GF120918 (pre-treatment and invasion, white bars). Alternatively, parasites were pre-treated with 10 mM GF120918 for 4 h, washed to remove the
drug and incubated with host cells in absence of GF120918 (only pre-treatment, gray bars). Invasion was quantified by enumerating the parasite
vacuoles at 24 h post infection. Data are average of vacuoles per field 6 SE (n=15) of a representative of 3 experiments. C. Adhesion/invasion assay
in presence of 10 mM GF120918 (GF) or solvent (cntl). Parasites were pre-treated with GF120918 for 30 min at 37uC and allowed to infect DKO host
cell monolayers for 2 h in presence of the drug (pre-treatment). Alternatively, drug pre-treatment was omitted and GF120918 added at the time of
invasion (no pre-treatment). Adherent (intracellular + extracellular) and invaded (intracellular) parasites were counted after dual color
immunostaining. Data are average of parasites per field 6 SE (n=15) of a representative of 3 experiments, normalized with respect to cntl
adhesion and expressed as percentage. D. Adhesion/invasion assay in presence of 10 mM GF120918 (GF) or solvent (cntl). Parasites were pre-treated
with GF120918 for 30 min at 37uCo r4 uC and allowed to infect DKO host cell monolayers for 15 min in presence of the drug. Parasites were counted
as in C. Data are average of parasites per field 6 SE (n=10) of a representative of 2 experiments, normalized with respect to cntl adhesion and
expressed as percentage. E. Adhesion/invasion assay in presence of 1 mM of the Ca
2+ ionophore A23187 (CaI) or solvent (cntl). Parasites were allowed
to infect DKO host cell monolayers for 2 h or 15 min in presence of the drug. Adherent and invaded parasites were counted after dual color
GF120918 and Toxoplasma Gondii
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egress was observed compared with untreated cells, whose egress
rate was consistently observed at 3–10% (Fig. 4A, w/o CaI).
Contrary to the natural egress which occurs at the end of the
parasite lytic cycle and does not require parasite motility [28], the
motility-dependent active egress is thought to be employed by the
parasite as an escape mechanism from a dying host cell [29]. To
determine whether the GF120918-mediated egress was caused by
host cell lethality, we analyzed the viability of host cells treated
with the inhibitor. Incubation with GF120918 for 24 h did not
reduce host cell viability, indicating that the increased egress
induced by GF120918 was not a response to inhibitor-mediated
host cell toxicity (Fig. 4B).
Next we analyzed the effect of GF120918 during experimental
induction of active egress. As with microneme secretion, active
egress can also be induced by adding the Ca
2+ ionophore A23187
[30], which raises intracellular calcium levels and activates parasite
motility (rev. in [31]). When parasite egress was induced with
A23187 incubation, a similar increase in egress was observed in
presence or absence of GF120918, indicating that GF120918
treatment was not able to further increase egress when used in
combination with the Ca
2+ ionophore (Fig. 4A, w CaI).
Intracellular localization of T. gondii P-gp
We showed that treatment of T. gondii with the P-gp inhibitor
GF120918 strongly correlated with alterations in Ca
2+-dependent
processes; thus, it is possible that P-gp plays a role in Ca
2+
regulation in this parasite. To investigate this hypothesis, we
analyzed whether P-gp localized in parasite organelles involved in
Ca
2+ homeostasis. For this aim we used the P-gp-specific
monoclonal antibody C219, which recognizes a conserved epitope
also present in the T. gondii orthologue (Genbank accession no.
AAZ04382) (Fig. S1B). Western blot analysis confirmed that the
antibody reacts with a parasite protein corresponding to the
predicted mass of P-gp (Fig. S1A). Immunoelectron microscopy of
infected cells showed a distinct staining concentrated in conspic-
uous membrane-bound electron-lucent vesicles of 100–400 nm
diameter. The plasma membrane of the parasite was less intensely
labeled with this antibody, and no staining of other vesicular
structures, such as rhoptries and dense granules was observed
(Fig. 5A). In addition, P-gp labeling was found in the tubulove-
sicular network within the parasite vacuole. Strikingly, P-gp
staining drastically increased in the rare vacuoles which contained
dying parasites, characterized by high intracellular vacuolization,
plasma membrane rupture and release of cytosolic content in the
parasite vacuolar space (Fig. 5B).
The P-gp labeled electron-lucent vesicles morphologically
resembled acidocalcisomes, the largest intracellular store of Ca
2+
in the parasite [32].Co-immunostaining with antibodies against
the acidocalcisome marker VP1 [33] revealed that both proteins
are indeed present in the same structures (Fig. 5C).
Next, we investigated the localization of P-gp by immunoflu-
orescence analysis. As the monoclonal antibody C219 is suitable
for this technique only in case of P-gp overexpression, we
engineered a P-gp minigene composed of three sequences of the
parasite protein showing low degree of similarity with the
mammalian P-gp (Fig S1B), and which encompassed the peptide
sequence used in a previous study to raise anti-T. gondii P-gp
antibodies [9]. Similar to the C219 antibody, the immune serum
against P-gp minigene reacted with a band of mass expected for P-
gp (Fig. S1A). As previously reported [9], lower molecular weight
bands were also detected; it is currently not known if they
constitute protein degradation or processing products. Immuno-
fluorescence analysis of T. gondii infected cells using the P-gp
minigene antibody showed a strong labeling of distinct intracel-
lular structures distributed throughout the cell and of plasma
membrane (Fig. 6A). Similar to the observations with electron
microscopy, these intracellular structures partially co-localized
with VP1 (Fig. 6A) but not with the microneme protein MIC4
(Fig. 6B), strongly suggesting that P-gp is indeed localized in
acidocalcisomes.
Interestingly, when extracellular T. gondii were probed with the
P-gp minigene antibody, a subgroup of parasites showed P-gp
labeling exclusively on the plasma membrane and labeling of the
internal structures was no longer evident. In addition, the staining
concentrated at the apical end of the parasite and formed a collar
around the conoid, which in turn remained unlabeled (Fig. 6C).
These results suggest that P-gp transiently re-localized in
extracellular parasites.
GF120918 treatment inhibits T. gondii replication and
lipid synthesis
To determine whether GF120918 treatment affected parasite
replication, P-gp DKO host cells were infected with T. gondii and
subsequently treated with different concentrations of the inhibitor.
Analysis of parasite burden 48 h post infection revealed a marked
dose-dependent inhibition of parasite replication (Fig. 7A).
Immunofluorescence analysis did not show any cells positive for
the bradyzoite-specific antigen BAG1 (data not shown), indicating
that GF120918 treatment reduced parasite replication without
triggering parasite stage conversion to the quiescent bradyzoite
form. Treatment with verapamil, an earlier generation P-gp
inhibitor reported to be less potent than GF120918 [34], was less
effective in blocking parasite replication. However, longer
incubation times with verapamil strongly inhibited T. gondii
replication as well (Fig. 7B), without affecting host cell viability
(data not shown). In addition, GF120918-mediated inhibition of
parasite replication was not reversed following removal of the
drug: parasites treated with the inhibitor prior to contact with host
cells not only showed defective invasion (Fig. 1B), but also formed
smaller vacuoles containing fewer parasites than control cells after
24 h incubation in the absence of the drug (Fig. 7C).
We previously showed that GF120918 induced egress of
intracellular parasites, albeit less potently than the Ca
2+ ionophore
A23187 (Fig. 4A). Next we determined whether increased parasite
egress contributed to the reduced parasite burden in cell cultures.
Freshly infected host cells were treated with GF120918 and
parasite vacuoles were enumerated after 30 h incubation.
Inhibitor treatment slightly decreased the number of vacuoles in
infected cells (Fig. 7D, left panel), possibly due to egressed parasites
and/or inhibition of host cell re-invasion (Fig. 1B, C). However,
analysis of parasite burden revealed a much more pronounced
decrease in the number of parasites contained in the vacuoles
(Fig. 7D, right panel, solid lines). In addition, when infected cells
were treated with GF120918 only in the last 4 of the 30 h
incubation, no difference in parasite distribution was observed
immunostaining. Data are average of parasites per field 6 SE (n=10) of a representative of 3 experiments, normalized with respect to cntl adhesion
and expressed as percentage. F. Isolated parasites were treated with 10 mM GF120918 (GF) or solvent (cntl) for 4 h at 37uC or heat killed (HK) for 1 h
at 65uC. Cell viability was assessed by measuring AlamarBlue reduction (Biosource) (A) or trypan blue exclusion (T). Results are average 6 SE (n=3 for
A and 8 for T) and expressed as percentage of cntl viability. *, p,0.05.
doi:10.1371/journal.pone.0010062.g001
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not selectively induce the egress of vacuoles containing high
numbers of parasites.
Collectively, these results suggest that GF120918-induced egress
may contribute to, but is not sufficient to account for the reduced
parasite burden observed in these experiments and that inhibitory
mechanisms directly acting on parasite replication are likely to
occur.
In search for the molecular mechanisms responsible for the
GF120918-mediated inhibition of parasite replication, we ana-
lyzed the effect of the inhibitor on T. gondii lipid metabolism, a
critical process for proper parasite replication. As we recently
showed that host P-gp is involved in cholesterol transport from the
host cell to the parasite vacuoles [11], we hypothesized that the
Figure 2. GF120918 treatment increases parasite motility. A.
Parasites were treated with 10 mM GF120918 (GF, white bars), 1 mM
Ca
2+ ionophore A23187 (CaI, gray bars) or the respective solvents (cntl)
and the trails deposited during gliding enumerated. Data are average of
trail number per field 6 SE (n=15) of a representative of 3 experiments
and expressed as percentage of cntl. B. Indirect immunofluorescence
microscopy (left panel) and trail length quantification (right panel)
demonstrating that the average length of trails increased with
GF120918 (GF) treatment. Data are percentage of short (,10 mM) or
long (.10 mM) trails per field 6 SE (n=10) of a representative of 2
experiments. C. Parasites were treated with 10 mM GF120918 (GF) in
presence or absence of 100 mM BAPTA and trail deposition was
quantified as before. Data are average of trail number per field 6 SE
(n=10) of a representative of 2 experiments and expressed as
percentage of cntl-treated parasites. *, p,0.05.
doi:10.1371/journal.pone.0010062.g002
Figure 3. GF120918 treatment increases MIC2 secretion. A.
Isolated parasites were treated with 10 mM GF120918 (GF) or solvent
(cntl) for 5 or 30 min, fixed and stained with anti-MIC2 antibody without
cell permeabilization. Central panel, magnification of T. gondii treated
with GF120918 for 30 min showing MIC2 surface staining. Insets,
differential interference contrast images. B. Isolated parasites treated
with 10 mM GF120918 (GF) or solvent (cntl) for 30 min were stained
with anti-MIC2 antibody without (thick lines) or with (thin lines) cell
permeabilization and quantified by flow cytometry. Overlay histogram
showing cells treated with solvent (cntl, yellow lines) or GF120918 (GF,
black lines). U, unstained cells.
doi:10.1371/journal.pone.0010062.g003
GF120918 and Toxoplasma Gondii
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with the P-gp inhibitor may derive from impaired lipid transport
and/or synthesis. To test this, we treated isolated parasites with the
inhibitor and monitored lipid synthesis after metabolic labeling.
The fatty acid precursor [
3H]palmitic acid was readily incorpo-
rated in phospho- and sphingolipid species of control parasites
(Fig. 7E). However, incubation with GF120918 induced a general
decrease in parasite lipid synthesis. Interestingly, the inhibitor did
not reduce the synthesis of all labeled lipids in a similar manner,
but differently affected the relative amount of the lipid species,
with PC synthesis being the most down-regulated while ceramide
synthesis was increased compared with control cells. Next, we
determined whether GF120918 affected not only lipid synthesis
but also lipid precursor uptake. Liquid scintillation analysis
revealed that inhibitor treatment strongly inhibited the incorpo-
ration of [
3H]palmitic acid in both total cell extracts and lipid
fraction (Fig. 7F). This reduced incorporation was specific for
[
3H]palmitic acid as incorporation of [
3H]choline was not affected
by GF120918 treatment. Collectively, these data show that
GF120918-induced inhibition of T. gondii replication was likely
mediated by a reduction in parasite lipid uptake and synthesis.
Down-regulation of T. gondii P-gp correlates with
reduced parasite replication and lipid synthesis
While T. gondii is able to grow in P-gp DKO host cells, its
replication rate is reduced due to defective cholesterol trafficking
to the parasite vacuole [11]. When we analyzed T. gondii
maintained for more than 4 lysis cycles in P-gp DKO host cells,
we found that the sub-optimal growth conditions did not trigger
parasite stage conversion to the quiescent bradyzoite form
(Fig. 8A). In addition, parasites isolated from P-gp DKO host
cells after more than 4 passages were able to infect (Fig. 8B) and to
egress from (Fig. 8C) new host cells as efficiently as parasites
maintained in WT host cells. These finding suggest that the lower
parasite burden observed was not caused by compromised
infection or exit from host cells, but by a specific defect in
replication, consistent with the limited access to host cholesterol
demonstrated previously [11]. However, when parasites isolated
from P-gp DKO host cells were allowed to infect WT host cells
with a normal cholesterol trafficking, their replication rate
remained slower compared with parasites isolated from WT host
cells, as monitored up to 72 h post infection (Fig. 8D and not
shown). While it is conceivable that cholesterol storage still
depleted in the parasite after prolonged growth in P-gp DKO host
cells affected T. gondii replication, it is also possible that lipid
transport and/or synthesis are altered in these parasites. To test
this hypothesis, we monitored the lipid synthesis in T. gondii
isolated from P-gp DKO host cells after more than 4 lysis cycles.
Surprisingly, [
3H]palmitic acid labeled cells showed an overall
decrease in lipid synthesis with a profile similar to what was
observed during P-gp inhibition with GF120918 (Fig. 8E). To
investigate whether the inhibition of lipid synthesis correlated with
inhibition of T. gondii P-gp, we performed real-time PCR (Fig. 8F)
and P-gp functionality assay (Fig. 8G) on parasites isolated from
WT or P-gp DKO host cells. Both approaches indicated that P-gp
expression and activity were reduced in parasites grown in P-gp
DKO host cells, supporting the correlation between lipid synthesis
and P-gp activity revealed by pharmacological P-gp inhibition.
Discussion
P-gp has been shown to be a major mechanism of multidrug
resistance in pathogenic organisms, including protozoan parasites
(rev. in [35]). However, the physiological roles of P-gp in the
absence of drug pressure remain poorly understood. In the present
study we investigated the effects of the potent, third generation P-
gp inhibitor GF120918 in the pathogenic parasite T. gondii.W e
found a dual role of GF120918 in the parasite physiology, namely
in Ca
2+-dependent processes and lipid synthesis.
GF120918 treatment and Ca
2+-regulated processes
Ca
2+ fluxes have been shown to play a key role in T. gondii
invasion by regulating the secretion of microneme proteins, which
serve as a bridge between the internal actin-myosin motor system
and external substrates, and thus mediate both T. gondii adhesion
and movement [36]. However, the molecular mechanisms
regulating Ca
2+ homeostasis in the parasite are not completely
elucidated [37]. Here we showed that GF120918 treatment
induced the secretion of the microneme protein MIC2 in absence
of contact with host cells. In addition, increased MIC2 secretion
correlated with increased parasite motility, in terms of number and
Figure 4. GF120918 treatment increases T. gondii egress. A. T.
gondii was allowed to replicate in P-gp DKO host cells for 30 h, treated
with 10 mM GF120918 (GF) or solvent (cntl) for 4 h and egress
quantified after parasite immunolabeling. For Ca
2+ ionophore (CaI)-
induced egress, infected monolayers were treated with GF120918 as
before and additionally incubated with 1 mM A23187 for 10 min. Data
are average of egressed parasites per field 6 SE (n=20) expressed as
percentage of cntl without CaI. Right panels, examples of intravacuolar
and egressed parasites. B. Metabolic activity of P-gp DKO host cells
treated for 24 h with solvent (cntl) or GF120918 (GF) at the indicated
concentrations was assessed by measuring AlamarBlue reduction
(Biosource). Results are average 6 SE (n=6).
doi:10.1371/journal.pone.0010062.g004
GF120918 and Toxoplasma Gondii
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Increased motility was not reported in a previous study using an
early generation P-gp inhibitor [6]. While the different methods
used by the authors to quantify parasite movement could account
for this discrepancy, another explanation derives from different
potency and binding capacity of the inhibitors to P-gp, which is
Figure 5. Ultrastructural localization of T. gondii P-gp. A. T. gondii was allowed to replicate in P-gp DKO host cells for 24 h and immunoelectron
microscopy performed with the anti-Pgp antibody C219. PVN, parasitophorous network; DG, dense granules; R, rhoptries; N, nucleus. Scale bars,
0.5 mm. B. Examples of P-gp localization in damaged parasite vacuoles. Scale bars, 1 mm. C. Co-localization of C219 (15 nm gold, arrows) and anti-VP1
(5 nm gold, arrowheads). Scale bars, 0.5 mm.
doi:10.1371/journal.pone.0010062.g005
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observed in replication and invasion assays. Consistent with a role
in promoting Ca
2+-mediated motility, GF120918 treatment
induced T. gondii egress from infected host cells, a process known
to depend on parasite motility and Ca
2+ fluxes [27].
Increased T. gondii motility has been reported only rarely, and is
generally characterized by fast and unregulated movement not
resulting in productive locomotion. Examples are treatments with
jasplakinolide, an actin filament stabilizer [38], or selected small
molecules identified in a screen for parasite invasion inhibitors
[39]. However treatment with calmidazolium, which increased
intracellular Ca
2+ levels in the parasite, induced both microneme
secretion and productive motility [40]. The mechanism of
calmidazolium-mediated increase of Ca
2+ levels has not been
identified in the parasite as yet; however the fact that chelation of
extracellular Ca
2+ decreased the calmidazolium-induced parasite
motility led to the hypothesis that the compound may promote the
influx of extracellular Ca
2+ by modulating a Ca
2+ transporter
Figure 6. Intracellular localization of T. gondii P-gp. Confocal microscopy of intracellular T. gondii at 24 h post infection. A. Dual staining using
polyclonal mouse anti-P-gp minigene (green) and anti-VP1 (red) antibodies showing partial co-localization of the two proteins (arrows). Nuclear DNA
was stained with DAPI. Merge, maximum projection; Merge’, single optical section of the deconvolved image stacks. B. Dual staining using anti-P-gp
minigene (green) and anti-MIC4 (red) antibodies. Merge, maximum projection; Merge’, single optical section of the deconvolved image stacks. C.
Wide field fluorescence (left panels) and 3D reconstructed confocal (right panels) micrographs showing differential P-gp distribution in extracellular
parasites stained with anti-P-gp minigene antibody (green). The arrow indicates the absence of P-gp staining in the conoid area labeled with anti-T.
gondii antibody (red). Nuclear DNA was stained with DAPI (blue). Scale bars: 5 mm.
doi:10.1371/journal.pone.0010062.g006
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subsequently treated with the indicated concentrations of GF120918 (GF) and verapamil (Ver). Parasite burden was quantified 48 h post infection by a
colorimetric assay measuring the amount of parasite-expressed b-galactosidase. Results are expressed as percentage of parasite number in control
untreated cells 6 SE (n=5). B. Time course of parasite replication inhibition by verapamil. T. gondii infected host cells were treated with the indicated
concentrations of verapamil or solvent (cntl). Parasite burden was quantified at the indicated times post infection as described above. Results are
expressed as percentage of parasite number in control untreated cells 6 SE (n=3). C. T. gondii were treated with 10 mM GF120918 (GF) or solvent (cntl)
for 4 h, washed and incubated with P-gp DKO host cells for 24 h in absence of the drug. Intracellular parasites were quantified by direct counting after
immunostaining. The distribution of the parasite number in single vacuoles is expressed as percentage of total vacuoles examined (n.100). D. Left
panel: parasites were allowed to infect host cell monolayers for 4 h, followed by 10 mM GF120918 (GF) or solvent (cntl) treatment for additional 26 h.
Vacuoles containing at least 2 parasites were enumerated at 30 h post infection after immunostaining. Data are average of vacuoles per field 6 SE
(n=10). Right panel: parasites were allowed to infect host cell monolayers for 4 h, and treated with 10 mM GF120918 (GF) or solvent (cntl) for 26 h or for
thelast 4 ofthe30 h incubation. Intracellular parasites werequantifiedbydirectcountingafterimmunostaining. Thedistributionoftheparasite number
in single vacuoles is expressed as percentage of total vacuoles examined (n.100). E. Isolated parasites were labeled with 0.5 mCi/mL of [
3H]palmitic acid
for 3 h in presence of 10 mM GF120918 (GF) or solvent (cntl) and lipid were extracted. Left panel, TLC separation of de novo synthesized lipids. Lipid
standard used: ceramide (Cer), glucosylceramide (GC), phosphatidylcholine (PC), sphingomyelin (SM). Right panel, quantification of the relative amount
of newly synthesized lipid species expressed as percentage of total lipids. Data are average 6 SE (n=3). F. Isolated parasites were labeled with 0.5 mCi/
mL of [
3H]palmitic acid or 4 mCi/mL [
3H]choline for 3 h in presence of 10 mM GF120918 (GF) or solvent (cntl). [
3H] incorporation was measured in both
whole cell (TOT) and lipid extracts by liquid scintillation and normalized by protein content. Data are average 6 SE (n=6).
doi:10.1371/journal.pone.0010062.g007
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PLoS ONE | www.plosone.org 9 April 2010 | Volume 5 | Issue 4 | e10062Figure 8. Down-regulation of T. gondii P-gp correlates with decreased lipid synthesis. A. Immunoflorescence analysis using antibodies
against the bradyzoite-specific antigen BAG1 showing the absence of parasite stage conversion into bradyzoites after more than 4 lysis cycles in P-gp
DKO host cells (upper panels). Lower panels, positive control of parasites induced to differentiate by alkaline treatment as described in the Materials and
Methodssection.Arrows, parasitevacuoles.DIC,differentialinterferencecontrastimages.B.Adhesion/invasionassayinWThostcellsofT.gondii isolated
from P-gp WT or DKO host cells after more than 4 lysis cycles. Adherent and invaded parasites were counted after dual color immunostaining. Data are
average of parasites per field 6 SE (n=10) and expressed as percentage of cntl adhesion of T. gondii maintained in WT host cells. C. The same isolated
parasites were allowed to replicate in WT host cells for 30 h, following induction of egress with 1 mM A23187 for 10 min. Data are average of egressed
parasites perfield 6 SE (n=15) expressed as percentage of the total (egressed + intravacuolar)parasites. D. Parasites isolated from P-gp WT or DKO host
cells after more than 4 lysis cycles were incubated with WT host cells for 24 h. Intracellular parasites were quantified by direct counting after
immunostaining. The distribution of the parasite number in single vacuoles is expressed as percentage of total vacuoles examined (n.100). E. Parasites
isolated from P-gp WT or DKO host cells after more than 4 lysis cycles were labeled with 0.5 mCi/mL of [
3H]palmitic acid for 3 h and lipid were extracted.
Left panel, TLC separation of de novo synthesized lipids. Lipid standard used: ceramide (Cer), glucosylceramide (GC), phosphatidylcholine (PC),
sphingomyelin (SM). Right panel, quantification of the relative amount of newly synthesized lipid species expressed as percentage of total lipids. Data
areaverage 6 SE(n=3). F.Semi-quantitative real timePCRofP-gp expression levelsin parasites isolatedfromP-gp WT or DKOhost cellsafter more than
4 lysis cycles. Gene expression levels were given as values in arbitrary units relative to the amount of the constitutively expressed house-keeping gene
tubulin. Data are average 6 SE (n=5). G. Functionality assay of P-gp in T. gondii isolated from P-gp WT or DKO host cells after more than 4 lysis cycles.
Parasites from WT host cells were treated with 5 mM GF120918 (GF) as positive control for inhibition of P-gp functionality. Intracellular rhodamine 123
(Rho 123) retention is expressed as percentage of mean fluorescence of intracellular Rho 123 at time 0.
doi:10.1371/journal.pone.0010062.g008
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our experimental conditions, extracellular Ca
2+chelation de-
creased the GF120918-induced parasite motility as well. The
striking similarity of the calmidazolium and GF120918 effect on
parasite motility strongly suggests that the two compounds operate
on a similar molecular mechanism and reveal a possible
involvement of P-gp in Ca
2+ signaling in the parasite. In addition,
it is possible that calmidazolium, which is marketed as a
calmodulin inhibitor, induced the T. gondii phenotype by
interfering with P-gp function, as Pgp is inactivated by calmodulin
antagonists [41]. Conversely, GF120918 has not been reported
thus far to interfere with Ca
2+ transport or Ca
2+-dependent
processes. Analysis of P-gp-dependent Ca
2+ fluxes is limited by the
fact that commonly used Ca
2+ indicators are known P-gp
substrates and are actively exported from the cell interior [42].
However studies performed with radiolabeled Ca
2+ in mammalian
cells indicated that this ion accumulated more in P-gp over-
expressing than in control cells [43–45]. Two P-type Ca
2+
transporters, the plasma membrane Ca
2+-ATPase (PMCA) and
the sarcoplasmic reticulum Ca
2+-ATPase (SERCA), play a crucial
role in maintaining Ca
2+ homeostasis. Both proteins counter-
transport protons and alteration of intracellular pH has been
shown to produce changes in Ca
2+ levels (Rev. in [46]).
Interestingly, P-gp expression has been associated with outward
proton movement and intracellular alkalinization as a conse-
quence of increased Cl
2/H
+ antiport [47]; similar data were also
obtained in the analysis of human P-gp over-expression in yeast
cells [48] and in the characterization of a bacterial P-gp
homologue [49]. While the direct mechanism regulating the P-
gp-mediated ion transport is not known, it is conceivable that P-gp
may play a role in Ca
2+ homeostasis by regulating cellular
concentration of protons and pH-dependent Ca
2+ transporters.
Ca
2+ regulation via PMCA and SERCA homologues is opera-
tional in T. gondii (rev. in [37,50]). Importantly, a PMCA-type
Ca
2+-ATPase (TgA1) involved in Ca
2+ influx, is localized to
acidocalcisomes, the largest Ca
2+ storage in T. gondii (rev. in [32]).
TgA1 deficiency reduced T. gondii invasion and decreased parasite
virulence [33], confirming that these organelles play an essential
role in Ca
2+ homeostasis and cellular processes in the parasite.
Surprisingly, our localization data revealed that P-gp was found
not only on the plasma membrane of the parasite, but also in
organelles morphologically resembling acidocalcisomes and la-
beled with the acidocalcisome marker VP1, further supporting a
P-gp involvement in Ca
2+ regulation. Similarly to the observations
with the acidocalcisome marker type I vacuolar-type H
+-
pyrophosphatase [51], P-gp transiently re-localized in a collar-
like structure at the apical end of extracellular parasites. Thus, we
can propose a model where P-gp may participate in the Ca
2+
homeostasis via facilitating Ca
2+ uptake in acidocalcisomes by
contributing to the establishment of the proton gradient in the
organelles and, in addition, via promoting the function of TgA1.
In addition, P-gp may also facilitate the activity of PMCA and its
inhibition would promote the entry of extracellular Ca
2+ and
increase parasite motility. In support of this hypothesis, chelation
of extracellular Ca
2+ reduced GF120918-stimulated parasite
motility.
P-gp has also been proposed as a regulator for Cl
2 selective
channels with a role in cell volume regulation [52]. As
acidocalcisomes have been implicated in maintaining ionic
homeostasis and regulating cell volume in Leishmania parasites
[53], it is tempting to speculate that T. gondii P-gp present in these
organelles may contribute to this regulatory function as well.
One intriguing finding of T. gondii treatment with GF120918
was the inhibition of host cell invasion despite increased
microneme secretion. Microneme secretion is necessary for a
successful host cell invasion; however several results suggest that it
is not sufficient to promote this process. Indeed, strong stimulation
of micronemes via prolonged Ca
2+ increase inhibits parasite
invasion ([21,22] and our study), presumably due to the exhaustion
of required invasion factors. A similar effect on T. gondii invasion
we monitored following GF120918 and Ca
2+ ionophore incuba-
tion suggested that a similar mechanism is responsible for the
observed time dependent inhibition. In addition, T. gondii deficient
for the acidocalcisome Ca
2+ transporter TgA1 also showed
increased and disregulated microneme secretion and invasion
inhibition [33]. Interestingly, no invasion defect was observed in T.
gondii with down-regulated P-gp expression, suggesting either that
the reduced P-gp activity may still be sufficient to guarantee a
normal infection rate, or that compensatory mechanisms are in
place to maintain proper Ca
2+ regulation.
GF120918 treatment and parasite replication
Our previous work demonstrated that functional host cell P-gp
is required for normal parasite replication [11]. In contrast with
mammalian cells where P-gp inhibition or absence does not affect
cell division, in this study we showed that GF120918 treatment
inhibits parasite replication. Our analyses also indicated that the
replication inhibition was likely caused by defective lipid synthesis,
as GF120918 treatment selectively reduced palmitic acid incor-
poration in both total cell and lipid extracts. Conversely the
normal choline incorporation in presence of GF120918 treatment
suggested that the observed defect in palmitic acid incorporation is
likely to occur also at the level of fatty acid uptake. The role of P-
gp as a lipid transporter/flippase has been confirmed using labeled
short chain lipid analogues [5]. In addition, the recently resolved
X-ray structure of P-gp revealed the presence of portals open to
both the cytoplasm and the inner leaflet of the plasma membrane,
consistent with a function as a lipid flippase [54]. However,
experiments with naturally occurring lipids are scarce and the
physiological role of P-gp in endogenous lipid transport is still
uncharacterized, with the only exception of platelet-activating
factor (PAF) [55]. T. gondii has been shown to scavenge not only
cholesterol [56], but also a variety of lipids from the host cells [57].
While the mechanisms by which host–derived lipids reach the
parasite are not completely elucidated, the formation of H.O.S.T.,
a unique system of tubular structures, has been proposed to be a
key event to sequester endo-lysosomes from the host cytoplasm
into the parasite vacuole, thus providing T. gondii with cholesterol
and possibly other lipids [58]. As our analyses showed that P-gp
localized also in the tubular structures forming the intravacuolar
network, it is tempting to speculate that parasite P-gp is involved in
the uptake of host–derived lipids, either directly or via modulation
of other transporters. A broad analysis of lipid transport by T.
gondii P-gp and related transporters will be an important area for
future investigation.
Quite surprisingly, our localization studies also revealed an
increased P-gp labeling in damaged parasite vacuoles, thus raising
the question of a possible role of P-gp during cellular stress in the
parasite. In support of this hypothesis, increased P-gp expression
was observed in mammalian cells after radiation exposure and was
associated with resistance to apoptotic signals and radioprotection
[59], indicating that P-gp plays a role not only in cell protection
during xenobiotic exposure, but also in cell survival during cell
damage.
Finally, we found unexpectedly that parasites grown in P-gp
deficient host cells had reduced P-gp expression. The molecular
mechanisms leading to P-gp down-regulation remain to be
determined. One possibility is that the reduced cholesterol content
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cholesterol depletion has been shown to down-regulate P-gp
expression [60]. Alternatively, the slower T. gondii replication rate
observed during infection of P-gp deficient host cells may result in
reduced P-gp expression. Consistent with this hypothesis, less
virulent T. gondii strains which are characterized by a slower
replication rate showed a reduced P-gp expression compared with
the virulent and fast replicating RH strain [9]. Finally, similar to
the observations in GF120918 treated cells, T. gondii with down-
regulated P-gp expression showed reduced lipid synthesis. This
correlation strongly supports a role of P-gp in lipid metabolism;
however, a contribution of slower parasite metabolism to the
observed compromised synthetic activity cannot be excluded.
In summary, this study demonstrated that GF120918 treatment
potently inhibits parasite invasion and replication, thus validating
the potential of P-gp inhibitors as a therapeutic strategy against T.
gondii. In addition, we also showed that GF120918 affected Ca
2+-
dependent processes and lipid metabolism in the parasite. While
our data on P-gp localization and expression are in support for a
direct involvement of P-gp in these events, additional investiga-
tions using genetic approaches will be required to exclude any
contribution of possible GF120918-mediated off-target effects and
to further our understanding of the function of P-gp and possibly
other ABC transporters in the biology of T. gondii.
Materials and Methods
Biochemical reagents
Unless otherwise stated, all chemicals were purchased from
Sigma and cell culture reagents from Gibco-BRL. GF120918 was
a kind gift of GlaxoSmithKline. Reagents stock solutions were
prepared at the following concentrations: 2 mM GF120918 in
DMSO, 10 mM BAPTA (1,2-bis (2-aminophenoxy) ethane-N, N,
N’, N’ tetracetic acid) in 0.3 M NaHCO3, 1 mM A23187 in
DMSO, 1 mg/mL rhodamine 123 in EtOH, 4.1 mM verapamil
in PBS. Reagents were freshly diluted to the concentrations
required for the individual experiment. Radiolabeled palmitic acid
and choline were purchased from Amersham Pharmacia Biotech.
Anti-P-gp monoclonal antibody C219 was purchased from Alexis
Biochemicals; anti-T. gondii MIC2 and VP1 were a kind gift from
J.F. Dubremetz (Universite ´ de Montpellier 2, Montpellier, France)
and S. Moreno (University of Georgia, Athens, GA), respectively.
Conjugated secondary antibodies were from Invitrogen. Lipid
standards were from Avanti Polar Lipids, Alabaster, Alabama.
Mammalian cell and parasite culture
Mouse embryonic fibroblasts (MEF) double knocked out (DKO)
for P-gp, (77.1, Mdr1a
-/-/Mdr1b
-/-) [3] and parental cells were
kindly provided by A. Schinkel (The Netherlands Cancer Institute,
Amsterdam, The Nederlands). Cells were routinely cultured in
Dulbecco’s modified Eagle medium (DMEM) supplemented with
10% fetal calf serum (FCS), 2 mM glutamine, 50 U of penicillin/
mL, and 50 mg of streptomycin/mL at 37uC with 5% CO2. b-
galactosidase expressing T. gondii were a kind gift from J.
Boothroyd (Stanford University School of Medicine, Stanford,
CA). T. gondii tachyzoites of the RH strain expressing Escherichia coli
b-galactosidase [61] were used in this study. Parasites were
maintained by serial passages in MEF, harvested from infected
host cells by passage through a 26-gauge needle and purified by
separation on Sephadex-G25 columns (Amersham) as described
[62]. Purified parasites were counted in a hemocytometer
chamber and used for a new cycle of host cell invasion.
For determination of parasite invasion, parasite were pre-
treated with 10 mM GF120918 for 30 min at 37uC and allowed to
infect for 4 h host cell monolayers at a multiplicity of infection
(MOI) of 3 in presence of the drug. Alternatively, parasites were
pre-treated with 10 mM GF120918 for 4 h, washed, and allowed
to infect host cell monolayers in absence of the drug. After removal
of residual extracellular parasites, infected cells were incubated for
20 h in absence of the drug and invasion was quantified by
enumerating the parasite vacuoles per field.
For adhesion/invasion assay, parasites were pre-treated with
10 mM GF120918 for 30 min at 37uCo r4 uC, incubated with host
cell monolayers at MOI 3 for 15 min at room temperature to settle
on the host cells and allowed to infect for 2 h or 15 min in a 37uC
incubator in presence of the drug. Alternatively, drug pre-
treatment was omitted and 10 mM GF120918 added at the time
of invasion for 2 h incubation. Parasites were analyzed by dual
color immunostaining with anti-T. gondii antiserum to differentiate
adherent (extracellular + intracellular) and invaded (intracellular)
parasites, as described [63]. A minimum of 20 parasites were
present per field examined.
For determination of parasite replication, host cell monolayers
were infected at a MOI of 3; parasite burden was quantified after
24 hrs by direct parasite counting or after 48 or 72 hrs by
colorimetric detection of parasite b-galactosidase using chloro-
phenol red-b-D galactopyranoside as substrate, as described [64].
During inhibitor analyses, GF120918 was added 2 h after
infection at the concentration indicated in the figure legends.
Bradyzoite differentiation was induced in vitro by alkaline
treatment as described [65]. Briefly, T. gondii tachyzoites were
allowed to infect host cell monolayer for 2 h and then the medium
was replaced with RPMI-1640 containing 1 g/L NaHCO3 and
50 mM tricine that had been adjusted to pH 8.1 with NaOH.
Cultures were incubated at 37uC and ambient CO2 for 4 days.
Cell viability assay
The metabolic activity of T. gondii and mammalian cells was
quantified using the AlamarBlueH assay (Biosource, Camarillo,
CA). Briefly, 1610
7 parasites were incubated at 37uC for 4 h with
10 mM GF120918 or heat killed at 65uC for 1 h and processed
according to the manufacturer instructions. Mammalian cells were
grown to confluence in 96 well plates, incubated for 24 h with
GF120918 at the concentrations indicated in the figure legend,
and processed according to the manufacturer instructions.
Viability of parasites was also tested by trypan blue exclusion.
P-glycoprotein functional assay
P-gp activity was assessed by cellular retention of the P-gp
substrate rhodamine 123 (Rho). Briefly, cells were incubated with
0.5 mg/mL Rho in PBS for 30 min at 37uC in presence or
absence of GF120918, at the concentrations indicated in the figure
legends. After washing in PBS, cells were incubated in medium at
37uC in absence or presence of the inhibitor for the time points
indicated in the figure legend. The kinetic of rhodamine retention
was quantified using a FACSCalibur flow cytometer (Becton &
Dickinson, Basel, Switzerland).
Motility assay
Motility was assayed by trail deposition visualization, as
described [39] with the following modifications. Freshly harvested
parasites were resuspended in HBSS containing 1% FCS and
10 mM Hepes, pre-treated with 10 mM GF120918 or DMSO for
15 min at 4uC, then added to poly-lysine coated slides (Thermo
Fisher, Portsmouth, NH) for 15 min at room temperature and
allowed to glide for 30 min at 37uC. After buffer removal, parasite
trails were fixed in PBS containing 3.6% formaldehyde, blocked
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by Alexa 488-conjugated goat anti-rabbit IgG, 1:200 dilution.
Egress
Egress was assayed as described [66], with the following
modifications. P-gp DKO MEF monolayers were grown on 10-
well glass slides (Thermo Fisher, Portsmouth, NH), infected with
T. gondii at an MOI of 3 and parasites were allowed to replicate for
30 h at 37uC. 10 mM GF120918 was added in the last 4 h of
replication, then cells were fixed with 3.6% formaldehyde, blocked
and stained with anti-T. gondii antiserum, 1:2000 dilution, followed
by Alexa 488-conjugated goat anti-rabbit IgG,1:200 dilution. For
induced egress, infected monolayers were treated with 10 mM
GF120918 as before, washed, incubated with 1 mM A23187 in
warm HBSS buffer for 10 min at 37uC and stained as described
before. Lysed and intact vacuoles were quantified and egress was
expressed as percentage of lysed vacuoles out of the total vacuoles
present in a given field.
Antibody production
T. gondii P-gp minigene was obtained by fusing three sequences
of the parasite protein (aa 1–52, 295–331, 625–755) showing low
degree of similarity with the mammalian P-gp. Oligonucleotides
(59-39 orientation) used in this study were:
s1 BamHI cgggatccATGGCCACCTCAGACGACTCATC,
as1 XbaI gcTCTAGA TTCT GTTCCAGAGACGAAGTG-
GAAC, s2 XbaI gctctagaGGACAAGTGATCTCCGACGGA
TTG, as2 EcoRI CGGAATTC AGCGTCGCCACCCT-
GAAACTCCAG, s3 EcoRI CGGAATTCATGAAAGACGA-
GAGCGGTCTG, as3 HindIII CCCAAGCTTAGGCCAGTAG
CGGAGAGCGAG.
The P-gp minigene was inserted downstream of the maltose
binding protein (MBP) in the plasmid vector pMal-2Cx (New
England Biolabs, MA). The fusion protein was produced in
transgenic Escherichia coli by induction with 0.3 mM IPTG
(isopropyl-b-D-thiogalactopyranoside) for 2 h at 37uC. Following
protein isolation by affinity purification on amylose resin
according to the manufacturers protocol (New England Biolabs,
MA), P-gp minigene was dialyzed, lyophilized and 150 mg used to
immunize intraperitoneally with RIBI adjuvant (Corixa, Hamilton
MT, USA) NMRI mice on days 0, 15, and 30 and 50.
Immunofluorescence analysis
Host cells infected with T. gondii or extracellular parasites were
fixed in 3.6% formaldehyde, permeabilized with 0.2% Triton X-
100 in PBS for 20 min, when indicated in the figure legends,
blocked and incubated with primary antibodies for 1 h. The
primary antibodies used in this study were: anti-T. gondii tachyzoite
rabbit antiserum [67], 1:2000 dilution, anti-T. gondii MIC2
monoclonal antiserum, 1:1000 dilution; anti-T. gondii MIC4 rabbit
antiserum, 1:1000 dilution; anti-T. gondii VP1 rabbit antiserum,
1:2000 dilution; anti-T. gondii BAG1 rabbit antiserum [68], 1:250
dilution; anti-T. gondii P-gp minigene mouse antiserum, 1:250
dilution. Fluorophore-conjugated secondary antibodies were used
at 1:200 dilution. Nuclei were visualized with 49, 6-diamidino-2-
phenylindole (DAPI).
Microscopy analyses were performed on a Leica DM IRBE
fluorescence microscope or on a Leica SP2 AOBS confocal laser-
scanning microscope (Leica Microsystems, Wetzlar, Germany),
using the appropriate settings. Image stacks of optical sections
were further processed using the Huygens deconvolution
software package version 2.7 (Scientific Volume Imaging,
Hilversum, NL).
Transmission electron microscopy analysis
P-gp DKO host cells were grown in 75 cm
2 flasks, infected with
T. gondii tachyzoites at MOI 1 and incubated at 37uC for 24 h
prior to fixation with 3% paraformaldehyde and 0.5% glutaral-
dehyde. Ultrathin sections were stained with anti-P-gp C219, 1:2
dilution, followed by 10 nm gold conjugated anti-mouse antibod-
ies, or double labeled with anti-P-gp C219, followed by 15 nm
gold conjugated anti-mouse antibodies, and anti-VP1, 1:250
dilution, followed by 5 nm gold conjugated anti-rabbit antibodies.
Sections were counterstained with uranyl acetate and lead citrate
and analyzed in a transmission electron microscope (CM12,
Philips, Eindhoven, The Netherlands) equipped with a CCD
camera (Ultrascan 1000; Gatan, Pleasanton, CA) at an acceler-
ation voltage of 100 kV.
Lipid analyses
For analysis of T. gondii lipid synthesis, purified parasites were
labeled with 0.5 mCi/mL [
3H]palmitic acid or 4 mCi/mL
[
3H]choline for 3 h in DMEM supplemented with 10% FCS.
After extensive washing with PBS and 0.05% fat free BSA in PBS,
lipids were extracted according to [69] and aliquots corresponding
to equal protein content were separated by high performance thin
layer chromatography (HPTLC) on Silica Gel 60 plates using
chloroform/methanol/25% NH4OH (65:25:4.5). Radiolabeled
bands were visualized by use of a tritium-sensitive screen
(Perkin-Elmer, Boston, MA) in a Personal Molecular PhosphoI-
mager FX (Biorad), identified according to co-migrating standards
(Avanti Polar Lipids, Alabaster, Alabama) visualized by iodine
vapors and quantified using ImageQuant software (Amersham,
Otelfingen, Switzerland). For determination of radioactivity
associated with total cell extract or lipid fraction, labeled cells
aliquots were solubilized in 0.1N NaOH or lipid extracted as
described above and radioactivity measured by liquid scintillation.
Semi-quantitative real time-PCR (RT-PCR)
RNA was isolated from 10
7 parasites isolated from WT or P-gp
DKO host cells after five lysis cycles using an RNAeasy kit
(Qiagen, Stanford, CA) following the ‘‘Animal Cells Spin’’
protocol. Residual genomic DNA was removed with DNase I
digestion according to the manufacturer’s protocol. First strand
cDNA synthesis was performed using ,250 ng RNA and
Omniscript reverse transcriptase (Qiagen), according to manufac-
turer’s protocol. Amplification was performed in an iCycler iQ
(Biorad, Hercules, CA) Primer pairs (59-39 orientation) used for
amplification of parasite tubulin (TUB), and P-gp were:
T.gTUB s CCAGGAGATGTTCAAG, T.gTUB as ACTCG-
GACACCAGGTCGTTC, T.gPgp s AAGGACAGCCGAAG-
GAAGAC, T.gPgp as GATGATGTCCGTCTGTGAC. Control
PCR showed absence of contamination from host cell RNA or
parasite genomic DNA. To assess the efficiency of the amplifica-
tion reactions, standard curves for every primer pair and cDNA
were generated from six-fold serial dilutions in duplicate, using the
iQ5 software. Expression levels of the genes were given as values in
arbitrary units relative to the amount of the constitutively
expressed house-keeping gene tubulin.
Western blot analysis
Cell lysates for immunoblots were prepared by sonicating cells
at 10
7/ml in 50 mM Tris-HCl (pH 6.8), 10% glycerol, 2% SDS,
5 mM DTT, 0.5 mM phenylmethylsulfonylfluoride and complete
protease inhibitor mixture (Calbiochem). Samples corresponding
to 40 mg proteins were mixed with SDS-PAGE loading buffer and
incubated 10 min at room temperature to prevent P-gp aggrega-
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transferred to nitrocellulose membranes, and probed using anti-
P-gp C219 (1:50), anti-T. gondii P-gp minigene (1:1000) and anti-
tubulin (1:2000) antibodies. Immunoreactive bands were visual-
ized with horseradish peroxidase-conjugated secondary antibodies
and enhanced chemiluminescence (ECL).
For analysis of MIC2 secretion, 100 mL aliquots containing
7610
7 parasites were incubated with 10 mM GF120918 or 1 mM
Ca
2+ ionophore A23187 for 30 min at 37uC. 80 mL of supernatant
were mixed with SDS-PAGE loading buffer, separated on 10%,
SDS-PAGE gels, transferred to nitrocellulose membranes, and
probed using anti-T. gondii MIC2 (1:1000) and anti-tubulin
(1:2000) antibodies.
Determination of protein concentration
Protein content was determined using the Bio-Rad Protein
Assay according to the instructions provided by the manufacturer.
Bovine serum albumin was used for the standard curve.
Statistical Analyses
Data are expressed as means 6 S.E. The statistical significance
of differences in the means of experimental groups was determined
using an unpaired, two-tailed Student’s t test using GraphPad
Prism 4.0c (GraphPad Software, Inc.) and a probability value
,0.05 was considered statistically significant.
Supporting Information
Figure S1 Detection of P-gp in T. gondii. A. Immunoblot
analysis of T. gondii extracts probed with the P-gp specific
monoclonal antibody C219 or with the anti-T. gondii P-gp
minigene antibody. Tubulin staining was used as a loading control.
Due to the low levels of P-gp expression compared with tubulin,
probed membranes were exposed for different times to record
unsaturated signal for both proteins. B. Protein sequence
alignment of T. gondii P-gp (Tgmdr1) with the two mouse
homologues. Highlighted in yellow are the sequences used to
create the P-gp minigene fusion protein. Red box, sequence used
in a previous study [1] to raise antibodies specific for T. gondii P-
gp. Green box, epitope recognized by the P-gp specific
monoclonal antibody C219. Gene bank accession numbers: T.g
mdr1, DQ094188; Mmdr1a, NP_035206; Mmdr1b, NP_035205.
Found at: doi:10.1371/journal.pone.0010062.s001 (2.96 MB TIF)
Figure S2 Detection of T. gondii MIC2 secretion. A. Immuno-
blot analysis of supernatant (SN) and pellets of T. gondii cultures
incubated with 10 mM GF120918 (GF), 1 mM of Ca2+ ionophore
A23187 (CaI) or solvent (cntl). Tubulin staining (Tub) was used as
a loading control. Due to the low levels of basal MIC2 secretion
compared with A23187- induced secretion, probed membranes
were exposed for longer times (asterisk) to record unsaturated
signal for both proteins. B. Densitometric quantification of the
relative amount of secreted MIC2, normalized by the total protein
amount, expressed as percentage of untreated control (cntl).
Found at: doi:10.1371/journal.pone.0010062.s002 (0.90 MB TIF)
Acknowledgments
We thank GlaxoSmithKline AG for their kind gift of GF120918
compound, Jean-Franc ¸ois Dubremetz, Dominique Soldati and Silvia
Moreno for kindly providing the anti-MIC2, anti-MIC4 and anti-VP1
antibodies and Mihaela Zavolan for bioinformatic analyses of T. gondii P-
gp. We are grateful to John Boothroyd for the b-galactosidase-expressing
T. gondii, Alfred Schinkel for kindly providing the P-gp deficient murine
embryonic fibroblasts and Therese Michel for technical assistance.
Author Contributions
Conceived and designed the experiments: SS. Performed the experiments:
IB US VO ABH SS. Analyzed the data: IB US VO ABH SS. Contributed
reagents/materials/analysis tools: ABH. Wrote the paper: SS.
References
1. Allikmets R, Gerrard B, Hutchinson A, Dean M (1996) Characterization of the
human ABC superfamily: isolation and mapping of 21 new genes using the
expressed sequence tags database. Hum Mol Genet 5: 1649–1655.
2. Higgins CF (1992) ABC transporters: from microorganisms to man. Annu Rev
Cell Biol 8: 67–113.
3. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, et al. (1997)
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-
transporting) P-glycoproteins. Proc Natl Acad Sci U S A 94: 4028–4033.
4. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, et al. (1992) Human P-
glycoprotein transports cortisol, aldosterone, and dexamethasone, but not
progesterone. J Biol Chem 267: 24248–24252.
5. Orlowski S, Martin S, Escargueil A (2006) P-glycoprotein and ‘lipid rafts’: some
ambiguous mutual relationships (floating on them, building them or meeting
them by chance?). Cell Mol Life Sci 63: 1038–1059.
6. Silverman JA, Hayes ML, Luft BJ, Joiner KA (1997) Characterization of anti-
Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking
immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: possible
role of a P glycoprotein in Toxoplasma physiology. Antimicrob Agents
Chemother 41: 1859–1866.
7. Sauvage V, Aubert D, Bonhomme A, Pinon JM, Millot JM (2004) P-
glycoprotein inhibitors modulate accumulation and efflux of xenobiotics in
extra and intracellular Toxoplasma gondii. Mol Biochem Parasitol 134: 89–95.
8. Sauvage V, Millot JM, Aubert D, Visneux V, Marle-Plistat M, et al. (2006)
Identification and expression analysis of ABC protein-encoding genes in
Toxoplasma gondii. Toxoplasma gondii ATP-binding cassette superfamily.
Mol Biochem Parasitol 147: 177–192.
9. Schmid A, Sauvage V, Escotte-Binet S, Aubert D, Terryn C, et al. (2009)
Molecular characterization and expression analysis of a P-glycoprotein
homologue in Toxoplasma gondii. Mol Biochem Parasitol 163: 54–60.
10. High KP (1994) The antimicrobial activities of cyclosporine, FK506, and
rapamycin. Transplantation 57: 1689–1700.
11. Bottova I, Hehl AB, Stefanic S, Fabrias G, Casas J, et al. (2009) Host cell P-
glycoprotein is essential for cholesterol uptake and replication of Toxoplasma
gondii. J Biol Chem 284: 17438–17448.
12. Wallstab A, Koester M, Bohme M, Keppler D (1999) Selective inhibition of
MDR1 P-glycoprotein-mediated transport by the acridone carboxamide
derivative GG918. Br J Cancer 79: 1053–1060.
13. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T (1993) In vitro and in vivo
reversal of multidrug resistance by GF120918, an acridonecarboxamide
derivative. Cancer Res 53: 4595–4602.
14. Tamai I, Tsuji A (2000) Transporter-mediated permeation of drugs across the
blood-brain barrier. J Pharm Sci 89: 1371–1388.
15. Zhang Y, Bachmeier C, Miller DW (2003) In vitro and in vivo models for
assessing drug efflux transporter activity. Adv Drug Deliv Rev 55: 31–51.
16. Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O
(2004) Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of
paclitaxel in mice. Invest New Drugs 22: 219–229.
17. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, et al. (2000) Inhibitory
effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1
Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 83: 366–374.
18. Ward KW, Azzarano LM (2004) Preclinical pharmacokinetic properties of the
P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-
methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-i soquinoliny-
l)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey.
J Pharmacol Exp Ther 310: 703–709.
19. Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, et al. (1996)
Flow cytometric assay of modulation of P-glycoprotein function in whole blood
by the multidrug resistance inhibitor GG918. Clin Cancer Res 2: 7–12.
20. Huynh MH, Rabenau KE, Harper JM, Beatty WL, Sibley LD, et al. (2003)
Rapid invasion of host cells by Toxoplasma requires secretion of the MIC2-
M2AP adhesive protein complex. Embo J 22: 2082–2090.
21. Carruthers VB, Giddings OK, Sibley LD (1999) Secretion of micronemal
proteins is associated with toxoplasma invasion of host cells. Cell Microbiol 1:
225–235.
22. Mondragon R, Frixione E (1996) Ca(2+)-dependence of conoid extrusion in
Toxoplasma gondii tachyzoites. J Eukaryot Microbiol 43: 120–127.
23. Soldati D, Meissner M (2004) Toxoplasma as a novel system for motility. Curr
Opin Cell Biol 16: 32–40.
GF120918 and Toxoplasma Gondii
PLoS ONE | www.plosone.org 14 April 2010 | Volume 5 | Issue 4 | e1006224. Hakansson S, Morisaki H, Heuser J, Sibley LD (1999) Time-lapse video
microscopy of gliding motility in Toxoplasma gondii reveals a novel, biphasic
mechanism of cell locomotion. Mol Biol Cell 10: 3539–3547.
25. Lovett JL, Sibley LD (2003) Intracellular calcium stores in Toxoplasma gondii
govern invasion of host cells. J Cell Sci 116: 3009–3016.
26. Carruthers VB, Sherman GD, Sibley LD (2000) The Toxoplasma adhesive
protein MIC2 is proteolytically processed at multiple sites by two parasite-
derived proteases. J Biol Chem 275: 14346–14353.
27. Moudy R, Manning TJ, Beckers CJ (2001) The loss of cytoplasmic potassium
upon host cell breakdown triggers egress of Toxoplasma gondii. J Biol Chem
276: 41492–41501.
28. Lavine MD, Arrizabalaga G (2008) Exit from host cells by the pathogenic
parasite Toxoplasma gondii does not require motility. Eukaryot Cell 7: 131–140.
29. Persson EK, Agnarson AM, Lambert H, Hitziger N, Yagita H, et al. (2007)
Death receptor ligation or exposure to perforin trigger rapid egress of the
intracellular parasite Toxoplasma gondii. J Immunol 179: 8357–8365.
30. Endo T, Sethi KK, Piekarski G (1982) Toxoplasma gondii: calcium ionophore
A23187-mediated exit of trophozoites from infected murine macrophages. Exp
Parasitol 53: 179–188.
31. Hoff EF, Carruthers VB (2002) Is Toxoplasma egress the first step in invasion?
Trends Parasitol 18: 251–255.
32. Miranda K, de Souza W, Plattner H, Hentschel J, Kawazoe U, et al. (2008)
Acidocalcisomes in Apicomplexan parasites. Exp Parasitol 118: 2–9.
33. Luo S, Ruiz FA, Moreno SN (2005) The acidocalcisome Ca2+-ATPase (TgA1)
of Toxoplasma gondii is required for polyphosphate storage, intracellular
calcium homeostasis and virulence. Mol Microbiol 55: 1034–1045.
34. Robert J (1998) Approaches to multidrug resistance reversal. Expert Opin
Investig Drugs 7: 929–939.
35. Sauvage V, Aubert D, Escotte-Binet S, Villena I (2009) The role of ATP-binding
cassette (ABC) proteins in protozoan parasites. Mol Biochem Parasitol 167:
81–94.
36. Jewett TJ, Sibley LD (2003) Aldolase forms a bridge between cell surface
adhesins and the actin cytoskeleton in apicomplexan parasites. Mol Cell 11:
885–894.
37. Moreno SN, Docampo R (2003) Calcium regulation in protozoan parasites.
Curr Opin Microbiol 6: 359–364.
38. Wetzel DM, Hakansson S, Hu K, Roos D, Sibley LD (2003) Actin filament
polymerization regulates gliding motility by apicomplexan parasites. Mol Biol
Cell 14: 396–406.
39. Carey KL, Westwood NJ, Mitchison TJ, Ward GE (2004) A small-molecule
approach to studying invasive mechanisms of Toxoplasma gondii. Proc Natl
Acad Sci U S A 101: 7433–7438.
40. Wetzel DM, Chen LA, Ruiz FA, Moreno SN, Sibley LD (2004) Calcium-
mediated protein secretion potentiates motility in Toxoplasma gondii. J Cell Sci
117: 5739–5748.
41. Ford JM (1996) Experimental reversal of P-glycoprotein-mediated multidrug
resistance by pharmacological chemosensitisers. Eur J Cancer 32A: 991–1001.
42. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, et al. (1993)
Fluorescent cellular indicators are extruded by the multidrug resistance protein.
J Biol Chem 268: 21493–21496.
43. Tsuruo T, Iida H, Kawabata H, Tsukagoshi S, Sakurai Y (1984) High calcium
content of pleiotropic drug-resistant P388 and K562 leukemia and Chinese
hamster ovary cells. Cancer Res 44: 5095–5099.
44. Sulova Z, Orlicky J, Fiala R, Dovinova I, Uhrik B, et al. (2005) Expression of P-
glycoprotein in L1210 cells is linked with rise in sensitivity to Ca2+. Biochem
Biophys Res Commun 335: 777–784.
45. Mestdagh N, Vandewalle B, Hornez L, Henichart JP (1994) Comparative study
of intracellular calcium and adenosine 39,59-cyclic monophosphate levels in
human breast carcinoma cells sensitive or resistant to Adriamycin: contribution
to reversion of chemoresistance. Biochem Pharmacol 48: 709–716.
46. Austin C, Wray S (2000) Interactions between Ca(2+) and H(+) and functional
consequences in vascular smooth muscle. Circ Res 86: 355–363.
47. Hoffman MM, Roepe PD (1997) Analysis of ion transport perturbations caused
by hu MDR 1 protein overexpression. Biochemistry 36: 11153–11168.
48. Fritz F, Howard EM, Hoffman MM, Roepe PD (1999) Evidence for altered ion
transport in Saccharomyces cerevisiae overexpressing human MDR 1 protein.
Biochemistry 38: 4214–4226.
49. Velamakanni S, Lau CH, Gutmann DA, Venter H, Barrera NP, et al. (2009) A
multidrug ABC transporter with a taste for salt. PLoS One 4: e6137.
50. Nagamune K, Moreno SN, Chini EN, Sibley LD (2008) Calcium regulation and
signaling in apicomplexan parasites. Subcell Biochem 47: 70–81.
51. Drozdowicz YM, Shaw M, Nishi M, Striepen B, Liwinski HA, et al. (2003)
Isolation and characterization of TgVP1, a type I vacuolar H+-translocating
pyrophosphatase from Toxoplasma gondii. The dynamics of its subcellular
localization and the cellular effects of a diphosphonate inhibitor. J Biol Chem
278: 1075–1085.
52. Valverde MA, Bond TD, Hardy SP, Taylor JC, Higgins CF, et al. (1996) The
multidrug resistance P-glycoprotein modulates cell regulatory volume decrease.
Embo J 15: 4460–4468.
53. Lefurgey A, Gannon M, Blum J, Ingram P (2005) Leishmania donovani
amastigotes mobilize organic and inorganic osmolytes during regulatory volume
decrease. J Eukaryot Microbiol 52: 277–289.
54. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, et al. (2009) Structure of P-
glycoprotein reveals a molecular basis for poly-specific drug binding. Science
323: 1718–1722.
55. Ernest S, Bello-Reuss E (1999) Secretion of platelet-activating factor is mediated
by MDR1 P-glycoprotein in cultured human mesangial cells. J Am Soc Nephrol
10: 2306–2313.
56. Coppens I, Sinai AP, Joiner KA (2000) Toxoplasma gondii exploits host low-
density lipoprotein receptor-mediated endocytosis for cholesterol acquisition.
J Cell Biol 149: 167–180.
57. Charron AJ, Sibley LD (2002) Host cells: mobilizable lipid resources for the
intracellular parasite Toxoplasma gondii. J Cell Sci 115: 3049–3059.
58. Coppens I, Dunn JD, Romano JD, Pypaert M, Zhang H, et al. (2006)
Toxoplasma gondii sequesters lysosomes from mammalian hosts in the vacuolar
space. Cell 125: 261–274.
59. Maier P, Fleckenstein K, Li L, Laufs S, Zeller WJ, et al. (2006) Overexpression
of MDR1 using a retroviral vector differentially regulates genes involved in
detoxification and apoptosis and confers radioprotection. Radiat Res 166:
463–473.
60. Rodrigues AC, Curi R, Hirata MH, Hirata RD (2009) Decreased ABCB1
mRNA expression induced by atorvastatin results from enhanced mRNA
degradation in HepG2 cells. Eur J Pharm Sci 37: 486–491.
61. Seeber F, Boothroyd JC (1996) Escherichia coli beta-galactosidase as an in vitro
and in vivo reporter enzyme and stable transfection marker in the intracellular
protozoan parasite Toxoplasma gondii. Gene 169: 39–45.
62. Hemphill A, Gottstein B, Kaufmann H (1996) Adhesion and invasion of bovine
endothelial cells by Neospora caninum. Parasitology 112 (Pt2): 183–197.
63. Hemphill A (1996) Subcellular localization and functional characterization of
Nc-p43, a major Neospora caninum tachyzoite surface protein. Infect Immun
64: 4279–4287.
64. Sonda S, Ting LM, Novak S, Kim K, Maher JJ, et al. (2001) Cholesterol
esterification by host and parasite is essential for optimal proliferation of
Toxoplasma gondii. J Biol Chem 276: 34434–34440.
65. Soete M, Camus D, Dubremetz JF (1994) Experimental induction of bradyzoite-
specific antigen expression and cyst formation by the RH strain of Toxoplasma
gondii in vitro. Exp Parasitol 78: 361–370.
66. Black MW, Arrizabalaga G, Boothroyd JC (2000) Ionophore-resistant mutants
of Toxoplasma gondii reveal host cell permeabilization as an early event in
egress. Mol Cell Biol 20: 9399–9408.
67. Fuchs N, Sonda S, Gottstein B, Hemphill A (1998) Differential expression of cell
surface- and dense granule-associated Neospora caninum proteins in tachyzoites
and bradyzoites. J Parasitol 84: 753–758.
68. McAllister MM, Parmley SF, Weiss LM, Welch VJ, McGuire AM (1996) An
immunohistochemical method for detecting bradyzoite antigen (BAG5) in
Toxoplasma gondii-infected tissues cross-reacts with a Neospora caninum
bradyzoite antigen. J Parasitol 82: 354–355.
69. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and
purification. Can J Med Sci 37: 911–917.
GF120918 and Toxoplasma Gondii
PLoS ONE | www.plosone.org 15 April 2010 | Volume 5 | Issue 4 | e10062